FILE:ALXN/ALXN-8K-20120928174527.txt.gz
EVENTS:	Other Events
TEXT:
ITEM: Other Events
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
_______________________
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): September 28, 2012
ALEXION PHARMACEUTICALS, INC.
-----------------------------------------------------------
(Exact name of registrant as specified in its charter)
352 Knotter Drive, Cheshire, Connecticut 06410
---------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrants telephone number, including area code:    (203) 272-2596
Item 8.01
    
Other Events.
On September 28, 2012, Dr. Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, Inc., reported sales of Alexion common stock made under pre-arranged stock trading plans adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Dr. Bell's currently existing pre-arranged stock trading plans adopted in accordance with Rule 10b5-1 for, among other things, estate and family financial planning, provide for the sale of up to an additional 356,900 shares of Alexion common stock. The sale of all or a substantial portion of such additional shares could occur during the 2012 tax year.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: September 28, 2012                ALEXION PHARMACEUTICALS, INC.
By:
    /s/ Michael V. Greco        
Name:    Michael V. Greco
Title:    Associate General Counsel and Corporate     Secretary


